Multiparametric magnetic resonance imaging/transrectal ultrasound fusion-guided prostate biopsy: a comparison with systematic transrectal ultrasound-guided prostate biopsy| JOURNAL OF GERONTOLOGY AND GERIATRICS

Abstract

Background and aims. Prostate biopsy is the standard method for diagnosing prostate cancer. Herein we compared the cancer detection rate of extended systematic Transrectal Prostate Biopsy with that of multiparametric Magnetic Resonance Imaging/Transrectal ultrasound fusion-guided Prostate Biopsy.
Methods. Outcomes of 99 fusion prostate biopsy (Group A) were compared with those of a matched population
of patients having undergone systematic transrectal prostate biopsy (Group B) in the same period.
Results. The overall cancer detection rate was 60.6% in Group A and 29,2% in Group B (p = < 0,001) whereas
the rate of clinically-significant prostate cancer was 26.2% in Group A and 13,1% in Group B (p = 0,02). At first
prostate biopsy the above-mentioned rates were 76% in Group A and 31,9% in Group B (p < 0,001), whereas
in repeated biopsy the rates were 34,7% in Group A and 18,6% in Group B (p = 0,08). Cancer detection rates
correlated well with the Prostate Imaging-Reporting and Data System; in the setting of first biopsy, it was 84,6,
67,8, 100% for score 3, 4 and 5, respectively, whereas in the setting of repeat biopsy it was 28,5, 55,5 and 80%
for score 3, 4 and 5, respectively. Complications rate was similar in both groups but all occurred in patients
> 75y.
Conclusions. Multiparametric Magnetic Resonance Imaging/transrectal ultrasound fusion-guided biopsy provided better prostate cancer detection rates than standard Prostate Biopsy in the setting of both first and
repeated Prostate Biopsy, showing good correlation between Prostate Imaging-Reporting and Data System
scores and cancer detection rates but complications were more common in elderly patients.